UNGER, THOMAS,KINTSCHER, ULRICH,SCHUPP, MICHAEL,KAUSCHKE, STEFAN,MARK, MICHAEL
申请号：
PL09160568
公开号：
PL2119441T3
申请日:
2004.07.24
申请国别(地区):
PL
年份:
2015
代理人:
摘要：
The use of the angiotensin II receptor antagonist telmisartan (I) (or its salt) and the 3-hydroxy-2-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor simvastatin (II) is claimed in the production of medicaments (A) for the treatment or prophylaxis of cardiovascular, cardiopulmonary or renal diseases. Independent claims are included for corresponding treatment methods and pharmaceutical compositions. ACTIVITY : Cardiant； Vasotropic； Hepatotropic； Hypotensive； Antilipemic； Antiarteriosclerotic； Antiasthmatic； Antiinflammatory； Antidiabetic； Cerebroprotective； Antianginal； Cytostatic； Antibacterial； Immunosuppressive； Vulnerary； Osteopathic； Neuroprotective； Nootropic. MECHANISM OF ACTION : Angiotensin II receptor antagonist； HMG-CoA reductase inhibitor； Peroxisome proliferator activated receptor-gamma (PPAR-gamma ) regulating gene expression inducer； Matrix metalloproteinase MMP-9 expression controller； Cytokine CD40L antagonist.
